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Pluripotent embryonic stem cells (ESC) have the ability to differentiate into a variety of cell lineages in 
vitro, including cardiomyocytes. Successful applications of ESC-derived cardiomyocytes in cell therapy 
and tissue engineering were limited by difficulties in selecting the desired cells from the heterogeneous 
cell population. We describe a simple method to generate relatively pure cardiomyocytes from mouse 
ESCs. A construct comprising mouse cardiac α-myosin heavy chain (MHC) promoter driving the 
neomycin resistance gene and SV40 promoter driving the hygromycin resistant gene designated pMHC-
neo/SV40-hygro, was stably transfected into mouse ESCs. The transgenic ESC line, designated MN6 
retained the undifferentiated state and the potential of cardiogenic differentiation. After G418 selection, 
more than 99% of cells expressed α-sarcomeric actin. Immunocytological and ultrastructural analysis 
demonstrated that, the selected cardiomyocytes were highly differentiated. Our results represent a 
simple genetic manipulation used to product essentially pure cardiomyocytes from differentiating ESCs. 
It may facilitate the development of cell therapy in heart diseases. 
 






Many cardiovascular diseases are associated with acute 
or chronic myocardial damage. Because cardiomyocytes 
cannot regenerate, loss of cardiomyocytes in the adult 
mammalian heart will lead to the formation of scar tissue 
and weaken the heart function, eventually causing heart 
failure (Delcayre and Swynghedauw, 2002). Recent studies 
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transplanted into damaged parts of the heart could 
improve cardiac function (Dimmeler et al., 2005; Hristov 
and Weber, 2006; Laflamme and Murry, 2005; Menasché, 
2008; Ye et al., 2006). This is a promising method for 
treatment of ischemic heart disease, but it requires a 
large number of myocardial cells. 
Embryonic stem cells (ESC) are pluripotent cells derived 
from the inner cell mass of blastocyst stage embryos.
 
They not only could proliferate unlimitedly in vitro, but 
also have the ability to differentiate into a variety of cell 
lineages, including caridomyocytes (Doetschman et al., 
1985). Based on these unique properties, ESCs should 
be currently one of the most promising sources of donor 
cardiomyocytes (Zimmermann and Eschenhagen, 2007). 
Although, the methods for induction of ESC differentiation 
into cardiomyocytes had already been reported, the 
percentage of cardiomyocytes in ESC-derived differentiated  




cells was very low. The heterogenous population still 
contained a large number of non-myocardial cells and 
some of the undifferentiated ESCs, which would be a 
serious impediment for clinical applications of ESC-
derived cardiomyocytes. Manual dissection of beating 
areas (Segev et al., 2005) and percoll gradient centri-
fugation (Xu et al., 2002) had been used to enrich 
cardiomyocytes, but the degree of purity would probably 
be insufficient for clinical or research purposes. 
In this study, we described the generation of transgenic 
mouse ESC lines transfected with a vector designated 
pMHC-neo/SV40-hygro containing two transcriptional units 
to allow selection of differentiating cardiomyocytes. This 
method was based on using a cardiac-specific α-myosin 
heavy chain (MHC) promoter to drive the expression of 
neomycin resistance gene. Expression of the transgene 
in ESC-derived cardiomyocytes facilitated their selection 
with G418 after in vitro differentiation. Immunocytological 
and ultrastructural analyses showed that, the selected 
cardiomyocytes exhibited the expected cardiac markers 
and were highly differentiated. Thus, we demonstrated 
that a relatively simple genetic selection could be used to 
generate pure cardiomyocytes from ESCs. 
 
 




The 5.5 kb mouse cardiac α-MHC promoter was amplified from 
mouse genomic DNA by polymerase chain reaction using LA Taq 
DNA polymerase (TaKaRa). Primers for cloning of α-MHC promoter 
fragment contained Mlu I (forward: 5’-GATC ACGCGT GGA TCC 
TGC AAG GTC ACA CAA GGG TCT CCA CCC AC-3’) and Nhe I 
(backward: 5’-GATC GCTAGC GTC GAC TCA AAC TCT TAT GGG 
GGA GAT AGG AGG GAT C-3’) restriction sites. The CMV promoter 
in pCMV/SV40-hygro vector (based on the pcDNA3.1 (+) from 
Invitrogen) was replaced by α-MHC promoter to generate 
pMHC/SV40-hygro after digestion with Mlu I and Nhe I. Then, the 
Nhe I-Not I restriction fragment containing the neomycin resistance 




ESC culture and transfection 
 
Mouse ESCs (ES-D3) were maintained in an undifferentiated state 
by culturing on a feeder layer of mitomycin C-treated mouse 
embryonic fibroblasts (MEF) on 0.1% gelatin-coated tissue culture 
dishes in ESC culture medium containing 85% high glucose DMEM 
(Invitrogen), 15% FBS (Hyclone), 0.1 mM β-mercaptoethanol 
(Sigma), 1% nonessential amino acids (Invitrogen) and 10
3
 U/ml 
leukemia inhibitory factor (LIF, Millipore). ESCs were passed by 
disassociating with 0.25% trypsin and 0.04% EDTA every second 
day. 5 × 10
6
 undifferentiated ESCs suspended in 800 µl PBS were 
transfected via electroporation (240 V/500 µF) with 50 µg 
nonlinearized pMHC-neo/SV40-hygro vector. 
 
 
Establishment of stably transgenic ESC lines 
 
After two days of recovery, the transfected cells were selected by 





days. The transgenic ESCs were digested by trypsinization for 3 
min and then counted and plated in 96 wells plates at a concen-
tration of a single cell/well covered with a layer of MEF. The single-
cell derived clones were chosen for expansion in hygromycin B-
supplemented ESC culture medium for an additional 7 days. 
Subsequently, the resulting stable cell lines were identified via 
genomic PCR using primers corresponding to the transfected 
plasmid. Primer sequences were: 5’-GAA AGT CAG GAC TTC ACA 
TAG AAG CCT AGC CCA CAC C-3’ (forward) and 5’-TCA GAA GAA 
CTC GTC AAG AAG GCG ATA GAA GGC G-3’ (backward). To 
verify that the transgenic ESC lines retained the undifferentiated 
state, the transgenic lines were stained for specific mouse ESC 





To induce differentiation, the transgenic ESCs were dispersed into 
individual cells using 0.25% trypsin and 0.04% EDTA, and preplated 
on tissue culture dishes for 60 min in differentiation medium (ES 
culture medium without LIF and replacing 15 for 20% FBS) to 
reduce the MEF and then inoculated into 100 mm Petri dishes at a 
density of 2 × 10
5
 cells/ml to form embryoid bodies (EB). After 5 
days in the suspension culture, the resulting EBs were plated onto 
0.1% gelatin-coated tissue culture dishes or 24 well plates in 
differentiation medium supplemented with 0.1 mg/ml ascorbic acid. 
The cultures were monitored daily under a phase contrast micro-
scope for the presence of contracting cardiomyocytes. 
 
 
Selection and dissociation of cardiomyocytes 
 
For selection of cardiomyocytes, the differentiation medium was 
supplemented with G418 (400 µg/ml) 12 days after induction to 
eliminate non-cardiomyocytes not expressing the neomycin resis-
tance gene. The differentiated cultures were subjected to G418 
selection for an additional 5 days before harvesting cardiomyocyte. 
For cell isolation, the selected cultures were washed with PBS and 
incubated with 0.05% trypsin and 0.02% EDTA at 37°C for 10 min. 
Cells were aspirated intensively by pipette for more complete 
dissociation. Dispersed cells were resuspended with fresh differen-
tiation medium and seeded on 0.1% gelatin-coated plates for 





After washing, the cultured cells were fixed with cold 4% 
paraformaldehyde for 15 min at room temperature. Alkaline phos-
phatase staining solution containing 50 mM NaCl, 100 mM Tris-HCl 
at pH 9.5, 50 mM MgCl2, 0.1% Tween-20, 1 mg/ml NBT (Sigma), 
0.1 mg/ml BCIP (Sigma) was added after washing. The reaction 
was incubated for 5 to 30 min at 37°C, and was stopped by addition 
of 10 mM EDTA. The wells were washed with PBS. Coloured colo-





Cells were rinsed briefly with PBS and fixed with 4% para-
formaldehyde at room temperature for 15 min. The fixed cells were 
washed three times in PBS and treated with 0.3% Triton X-100 for 
30 min. Unspecific binding sites was blocked by 5% BSA for 30 min. 
The primary antibodies were applied without washing and 
incubated at 4°C overnight. After washing, cells were treated with 
the secondary antibodies for 2 h at room temperature in the dark. 



















































Figure 1. Establishment of stably transgenic ESC lines. (A) 
Structure of the vector pMHC-neo/SV40-hygro. The plasmid 
backbone was pcDNA3.1(+); (B) identification of stably transfected 
mouse ESC clones via genomic PCR using primers specific for the 
transfected plasmid. White asterisk presents positive clones 
revealing the expected band of 889 bp; white triangle presents 




at room temperature for 40 min. Nuclei were stained with 0.1 µg/ml 
of DAPI (Sigma) at room temperature for 15 min. The primary 
antibodies used were mouse monoclonal anti-SSEA-1 (Santa Cruz, 
1:50),  rabbit  polyclonal  anti-Oct-4  (Cell  Signaling,   1:50),  mouse  




monoclonal anti-Troponin T (Maixin, 1:100), mouse monoclonal 
anti-α-sarcomeric actin (Maixin, 1:100) and mouse monoclonal anti-
α-sarcomeric actinin (Boster, 1:100). The second antibodies were 






Total RNA was extracted from the undifferentiated MN6 cells, 
differentiated EBs and G418-selected cells using TRIzol (Invitrogen) 
according to the specification indicated by the manufacturer. RNA 
was quantified by UV spectrophotometer. RT-PCR was performed 
with 1 µg of RNA per sample using PrimeScript one step RT-PCR 
kit Ver.2 (TaKaRa). The primers and sequences are listed in Table 1 
for GATA-4, Nkx2.5, α-MHC, β-MHC, MLC-2v, Oct-4 and GAPDH. 8 






Selected cell cultures were fixed in 2% glutaraldehyde, followed by 
postfixation in 2% osmium tetroxide. After subsequent overnight 
wash in PBS at 4°C, samples were dehydrated and embedded in 
epon. After trimming, the block was ultrathin sectioned and stained 
with uranyl acetate and lead citrate. Specimens were examined 





Establishment of stably transgenic ES lines 
 
The construct pMHC-neo/SV40-hygro containing two 
transcriptional units in a pcDNA3.1 (+) vector backbone 
was generated (Figure 1a). The first unit consisted of 
SV40 promoter and the hygromycin resistance gene used 
to select stably transfected ESCs before differentiation. 
The second unit contained α-MHC promoter driving the 
neomycin resistance gene used for selection of cardio-
myocytes. Six stable transgenic mouse ESC lines were 
generated and identified via genomic PCR analysis with 
primers specific for the transfected plasmid (Figure 1b). 
One line, designated MN6 (Figure 2a) demonstrating 
robust and homogenous expression of the transgene, 
was chosen for propagation and subsequent analyses. 
MN6 cells exhibited a strong AKP activity (Figure 2b). 
They still expressed mouse ESC markers Oct-4 and 
SSEA-1 (Figure 2c, d). These results showed that, the 
transgenic ESC lines retained the undifferentiated state. 
 
 
Induction of cardiogenic differentiation 
 
We next sought to determine whether expression of the 
pMHC-neo/SV40-hygro transgene impacted negatively 
on cardiogenic differentiation of the transgenic mouse 
ESCs. Following selection and expansion of the stably 
transfected undifferentiated colonies, MN6 cells were 
allowed to differentiate by inducing EB formation. After 5 
days  in  suspension  culture, EBs were plated on gelatin- 






Figure 2. Characterization of the pluripotent properties of the transgenic mouse ESC line, MN6. (A) Phase 
contrast observation of colonies of undifferentiated MN6 cells; (B) alkaline phosphatase positive colonies 
showed purple; (C) Oct-4 immunostaining of MN6 cells showed green; (D) SSEA-1 showed red, nuclei 




coated tissue culture dishes and observed using light 
microscopy for the presence of beating cells. MN6 
showed a similar developmental pattern with the wild-
type ESC lines. EBs attached and continued to proliferate 
and differentiate into a heterogeneous population of cells, 
including beating cardiomyocytes. Spontaneously, cont-
racting cells appeared as clusters after 2 days of 
adherence and induction. About 25% of EBs displayed 
contracting areas at differentiation day 10 and increased 
to as many as 70% of EBs by day 18. The percentage of 
beating EBs usually increased over time, reaching a 
maximum 18 days after differentiation (Figure 3a). After 
30 days, the number of beating EBs decreased due to the 
overgrowth of other cells. Immunofluorescence analysis 
showed  that,  only  a  small  percentage  of differentiated 
cells expressed cTnT (Figure 3b), indicating that the 
majority of cells were not cardiomyocytes. 
 
 
Selection of cardiomyocytes 
 
After 12 days of induction, G418 selection was imposed 
and differentiated cells were cultured for additional 5 
days. Selected cells were visibly spontaneous contracted 
with a rhythm of approximately 1 Hz, indicating a relatively 
pure population of cardiomyocytes. To determine the 
extent of cardiomyocytes enrichment obtained by genetic 
selection, the selected cultures were digested with trypsin 
and replated at a suitable density for immunocytologic 
analysis of individual cells. 






Figure 3. Differentiation of cardiomyocytes from the transgenic mouse ESCs. (A) Percentage of beating EBs derived from MN6 
cells during differentiation; (B) EBs were transferred to gelatin-coated plates after 5 days in suspension culture to allow further 
differentiation into a heterogeneous cells, including cardiomyocytes that were positive for cTnT (green). Nuclei staining with DAPI 




Table 2. Cardiomyocytes content in the unselected and G418-selected differentiated cells. 
 
Preparation 
α-Sarcomeric actin positive 
cell 
α-Sarcomeric actin negative 
cell 
Percentage of cardiomyocyte 
(%) 
No selection 13 1968 0.66 






Figure 4. G418 selection of cardiomyocytes derived from transgenic mouse ES lines. (A) Only a very few cells in 
differentiated cultures were cadiomyocytes positive for α-sarcomeric actin without G418 selection; (B) although a difference 
in fluorescence intensity was observed among cells, more than 99% of G418-selected cells expressed α-sarcomeric actin 




Immunocytochemistry was used to demonstrate purity 
of the enriched cell population. Although, a difference in 
fluorescence intensity was observed among cells, more 
than 99% of G418-selected cells expressed cardiac 
markers α-sarcomeric actin indicating an efficient enrich-
ment of cardiomyocytes in agreement with previous 
findings.  In contrast, only a very few cells in differentiated 
cultures were cardiomyocytes without G418 selection 
(Table 2 and Figure 4). Confocal microscopy was used to 
characterize G418-selected cells and confirm the extent 
of differentiation. The selected cells exhibited a typical 
cardiac morphology and formed the characteristic myofila-
ments. Well-developed sarcomeric structures were 
detected  by cTnT and α-actinin immunocytology (Figure 5). 






Figure 5. Confocal microscopy observation of immunofluorescence staining of G418-selected cardiomyocytes. Well-developed 
myofibrillar structures were detected using cTnT (A) and α-actinin (D) immunocytology and actin filaments (B, E) were labeled 






Figure 6. RT-PCR analysis of undifferentiated ESCs (1), 
differentiated EBs (2) and G418-selected cells (3). G418-selected 
cells expressed genes GATA-4, Nkx2.5, α-MHC, β-MHC and MLC-




RT-PCR results showed that G418-selected cells 
expressed genes GATA-4, Nkx2.5, α-MHC, β-MHC and 
MLC-2v. Undifferentiated ESCs expressed the pluripotent 
marker Oct-4 and did not express these cardiac-specific 
genes. Expression of Oct-4 in differentiated cultures of 
EBs decreased, whereas Oct-4 was not detected in G418-
selected cardiomyocytes (Figure 6). The results indicated 






The G418-selected cardiomyocytes exhibited sponta-
neous and rhythmic contractile activity. Ultrastructural 
analyses further demonstrated the differentiated status of 
cardiomyocyte cultures. Parallel arrays of myofibrillar 
bundles were apparent and the formation of early and 
more developed Z bands could be observed in many of 
the selected cardiomyocytes (Figure 7a). Desmosomes 
and gap junctions were observed to connect adjacent 
cells  (Figure 7b, c).  Myosin  synthesis  was  observed to  






Figure 7. Ultrastructural analysis of selected cardiomyocytes. (A) Transmission electron micrograph of G418-selected 
cardiomyocytes. n, nucleus; m, mitochondria; s, sarcomere; z, Z band; (B) high-power electron micrograph showing the presence 
of a desmosome (d); (C) high-power electron micrograph demonstrating the laminar structure of the gap junction (gj); (D) high-










ESC-derived cardiomyocytes have several potential 
applications including cell transplantation for myocardial 
repair, but the heterogeneity of differentiated cells derived 
from ESCs represents a considerable hurdle for widespread 
use of these cells in scientific and clinical applications. 
This highlights the requirement for effective strategies to 
enrich cardiomyocytes. In this report, we described the 
establishment of transgenic mouse ESC lines that allowed 
selection of differentiated cardiomyocytes. This method is 
based on using a cardiac-specific α-MHC promoter to 
drive the expression of neomycin resistance gene. ESC-
derived cardiomyocytes expressing the fusion gene could 
survive after G418 selection. In contrast, non-
cardiomyocytes  derived  from  transgenic  ESCs  did not 
express neomycin resistance gene and consequently 
were eliminated by G418 selection. The selected cells 
were stained positively for cardiac-specific proteins, 
expressed cardiac-specific genes and were highly 
differentiated. 
Myosin is the main component of thick filaments of 
cardiac sarcomere and consists of the heavy chain and 
light chain proteins. In cardiac muscle, two MHC isoforms 
were present, namely α-MHC and β-MHC. β-MHC is the 
predominant isoform during embryogenesis and fetal 
development, but in the post-birth period, α-MHC 
becomes the major form in adult myocardium (Liew and 
Jandreski, 1986). Gulick et al. (1991) described the 
isolation of mouse cardiac MHC locus and the character-
ization of the promoter region of the α-cardiac MHC gene 
with respect to its ability to direct expression of the CAT 
gene in myocardium in a tissue-specific manner. The use 
of cardiac-specific promoters for successful selection of 
cardiomyocytes was previously reported (David et al., 
2008;  Fijnvandraat  et  al., 2003; Huber et al., 2007; Klug  




et al., 1996; Kolossov et al., 1998). We isolated mouse α-
MHC promoter and constructed a vector α-MHC-EGFP to 
enable cardiac-specific EGFP expression. Neonatal 
mouse cardiomyocytes transfected α-MHC-EGFP could 
appear green fluorescence, but cardiac fibroblasts trans-
fected positively did not express EGFP (He et al., 2009). 
We also demonstrated that α-MHC promoter had the 
ability to drive the specific expression in myocardial cells 
and would be suitable for selection of ESC-derived 
cardiomyocytes. 
Interestingly, the transgenic mouse ESCs retained the 
ability to propagate in undifferentiated state, because the 
ESC colonies were stained positively for mouse ESC 
markers SSEA-1 and Oct-4, as well as a strong AKP 
activity. Expression of the pMHC-neo/SV40-hygro trans-
gene also did not impact negatively on cardiogenic 
differentiation, as evidenced by their ability to differentiate 
into spontaneously beating cardiomyocytes when com-
pared with wild-type lines. However, α-MHC promoter is 
active in the entire adult heart including a trial and pace-
maker cells and do not possess specificity distinguishing 
between different types of cardiomyocytes (Müller et al., 
2000). All the different cardiac phenotypes would be 
positively selected by α-MHC promoter-based enrichment 
method. Refinement of the selection procedure should be 
possible by choosing an appropriately cell type-restricted 
promoter. Combinatorial approaches using multiple 
promoters and selectable markers also can be envisioned 
(Anderson et al., 2007; Kolossov et al., 2005). 
Cell transplantation as a potential therapy for heart 
disease has been extensively demonstrated (Laflamme 
and Murry, 2005). Although, several types of cells have 
been transplanted into the hearts of experimental 
animals, cardiomyocytes are theoretically the best candi-
date donor cell to restore lost cardiac function because of 
their intrinsic electrophysiological, structural and contractile 
properties, which collectively allows them to functionally 
integrate with the host myocardium. To achieve cellular 
transplantation in larger animals and humans, a higher 
number of cardiomyocytes will be required. We recently 
showed that treatment of EBs with ascorbic acid is 
advantageous (data not shown). Another possibility to 
increase the quantity of differentiating cardiomyocytes 
might be employing a sequential cytokine induction proto-
col (Yang et al., 2008). However, the inherent variability of 
cardiogenic induction in differentiating ESCs can have a 
significant impact on the ultimate yield. The yield of 
G418-selected cardiomyocytes currently is somewhat 
variable, but it is likely that optimization and standardi-
zation of the induction and selection protocols will result 
in improved and reproducible preparations. 
Most importantly, the ability to select and generate pure 
cardiomyocytes may be very important for the future 
utilization of human ESCs in cell replacement therapy. 
The presence of any remaining pluripotent stem cells in the 
cell grafts may result in ESC-related tumors such as 
teratomas (Gepstein, 2002). Our results showed that 





sarcomeric actin and the pluripotent marker Oct-4 was 
not detected in G418-selected cells. Genetic enrichment 
was effective for purification of cardiomyocytes derived 
from ESCs. However, it still needs extensive studies in 
future to ensure the security of cell therapy. Regardless of 
stem cell source, the approach described here provides a 
useful tool to generate relatively pure cardiomyocytes for 
cell transplantation. The next challenge will be to deter-
mine the most effective route to scaling up production of 
ESC-derived cardiomyocytes and to test functional 
integration in animal models with cardiac dysfunction. 
Furthermore, it will be of great interest to transfer the 
promoter-based approach to the recently described ESCs 
derived from somatic cell nuclear transfer (Byrne et al., 
2007), as well as to induced pluripotent stem cells
 
(Yu et 
al., 2007). This may be the basis for future autologous 
cellular sources and future clinical use of cardiovascular 
progenitor cells. 
In summary, this report describes the generation of 
unique transgenic mouse ESC lines allowing selection of 
pure cardiomyocytes. This ability may have important 
implications for several cardiovascular research fields, 
including basic developmental studies, pharmacological 
and physiological studies, cell therapy and tissue engine-
ering. The selection procedure should be applicable to all 
ESC-derived cell lineages, provided that suitable lineage-
specific promoters are available. It is likely that, ESC-
derived cellular transplantation strategies can be extended 
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